Pump it
Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study
Summit Therapeutics Inc. shares fell nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
1
举报
登录后可参与评论
![empty](https://c1.itigergrowtha.com/community/assets/media/empty-default.06ba11e0.png)
暂无评论